companydata.dkHemab ApS: Financial statements 2023
CVR: 40837590
Hemab ApS (CVR 40837590) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK -22,783,000 compared with DKK -156,407,000 the year before. Equity amounted to DKK 136,196,000. The solvency ratio was 97.6%. The company had 21 employees in the financial year.
- Profit/Loss
- -22,783,000 kr.
- Equity
- 136,196,000 kr.
- Total Assets
- 139,476,000 kr.
- Employees
- 21
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | -22.8 mio. | 136.2 mio. | 21 |
| 2022 | - | - | -156.4 mio. | 6.1 mio. | 10 |
| 2021 | - | - | -35.2 mio. | 68 mio. | 3 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Hemab ApS has published its annual report for 2022. The net result was DKK -156,407,000.
As of March 1, 2023, Johan Henrik Faber has stepped down as director of Hemab ApS.
As of February 15, 2023, Benny Sørensen has joined the board of directors of Hemab ApS.
As of February 15, 2023, Daniel Becker has joined the board of directors of Hemab ApS.
As of February 15, 2023, Uya Chuluunbaatar has joined the board of directors of Hemab ApS.
As of February 15, 2023, Thomas Dal Stenfeldt Batchelor has left the board of directors of Hemab ApS.
About Hemab ApS
Hemab ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab Hemophilia ApS. The management consists of Benny Sørensen and Mads Nikolaj Behrndt-Eriksen. The company is owned by Hemab Therapeutics Holdings, Inc.. Equity amounted to DKK 196,000.